Rapid Response from San Francisco: The Latest in the HCV Treatment Revolution
|
|
- Laura Holmes
- 6 years ago
- Views:
Transcription
1 Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education Please be respectful of this request so we may continue to provide you with presentation materials. 15 Vindico Medical Education
2 Learning Objectives Review clinical advances for treating special populations of patients with HCV, including those with renal impairment and other comorbidities. Describe emerging clinical considerations underlying the management of HCV. Evaluate the safety, efficacy, and recommended usage of recently-approved and emerging direct-acting antiviral (DAA) agents for the management of HCV. Agenda Emerging Clinical Considerations Toward a Cure for All Patient Populations An Update on Recently-approved and Emerging DAA Regimens 15 Vindico Medical Education
3 Subpopulation Emerging Clinical Considerations Norah Terrault, MD, MPH Professor of Clinical Medicine and Surgery University of California, San Francisco Director of Viral Hepatitis Research in Liver Transplantation Department of Gastroenterology/Hepatology University of California, San Francisco San Francisco, CA HCV-TARGET: SVR1 and Relapse Rates for LDV/SOF ± RBV by Treatment Duration in HCV G1 Patients 1 LDV/SOF SVR Relapse 1 LDV/SOFRBV /154 4/154 7/7 /7 15/11 8/11 8 Weeks 1 Weeks 4 Weeks Terrault N, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract /89 1/89 1/1 1/1 1 Weeks 4 Weeks SVR1: SVR at 1 (±1) weeks post treatment HCV-TARGET: SVR1 with LDV/SOF Therapy by Subgroups All Cirrhotic Non-cirrhotic HCV<1 mln HCV>=1 mln Genotype 1a Genotype 1b Geno 1a Cirrhotic Geno 1b Cirrhotic Naïve Experienced No Prior OLT Prior OLT Decompensated Non-decompensated No baseline PPI Baseline PPI SVR1 LCL (95%) UCL (95%) rate (%) SVR Rate (%) Completed treatment as of 7/1/15 and have available virological outcomes. Patients who discontinued due to AE or were lost to follow-up are excluded. SVR1: SVR at 1 (±1) weeks post treatment Includes patients receiving 8 (n=154), 1 (n=7), 4 (n=11) and other (n=7) week of therapy Terrault N, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract Vindico Medical Education
4 SVR Rates (%) SVR1, % TRIO: SVR1 Rates by Regimen 1% 94% 97% 78% 91% 9% 8% 7% % 5% 4% % % 1% 14/151 74/7 /41 4/47 % LDV-SOF LDV-SOF SMVSOF D RBV /-RBV /-RBV Relapse 44 Relapse Relapse 5 Relapse Death Death Death Death LTFU LTFU 1 LTFU 4 LTFU 1 DC 9 DC 1 DC DC 1 Afdhal NH, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-17. ombitasvir/paritaprevir/ritonavir dasabuvir (D) TRIO: 149 Patients Were Treated Outside of FDA Guidelines and Saw a Significantly Lower SVR Rate (84% SVR Outside vs 95% SVR Inside) Inside vs Outside FDA Guidelines LDV-SOF /-RBV D /-RBV SMVSOF /-RBV Total Outside FDA Guidelines Inside FDA Guidelines 85% (115/15) 95% (191/14) Total 94% (15/1597) 8% (5/) 9% (8/41) 91% (4/47) % (5/8) 8% (7/) 78% (/41) 84% (15/149) 95% (145/15) 94% (1581/185) *Patients outside of guidelines: GT1a on D without RBV, tx failure cirrhotic patients on 1 weeks of D/-RBV, LDV-SOF without RBV, or SMVSOF/-RBV ombitasvir/paritaprevir/ritonavir dasabuvir (D) Afdhal NH, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-17. VA s National HCV Clinical Case Registry SVR Rates: Treatment Naïve, GT LDV/SOF * * LDV/SOFRBV * / 47/ 145/ 14/ 15 5/ 8/ 41/ 15/ / 1/ / 74/ 4/ 4/ 74/ / D<15 Overall African-America Caucasian FIB-4.5 FIB-4 >.5 UD D 15 No significant differences in unadjusted SVR rates based on age, sex, decompensated liver disease, diabetes, HIV coinfection, BMI, baseline HCV RNA, subtype and IL8B polymorphism. P<.1 *P<.1 Backus LI, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 9. Week 4 On Treatment HCV RNA 15 Vindico Medical Education
5 SVR1 (%) SVR1 (%) Rapid Response from San Francisco: NS5A Resistance Testing and Management Considerations Efficacy of LDV-SOF in Patients With and Without NS5A RAVs at Baseline With RAVs No RAVs Without cirrhosis / 17/18 187/189 54/59 79/88 98/ LDV/SOF 8 Weeks LDV/SOF 1 Weeks LDV/SOF 1 Weeks TN < M TN TE Zeuzem S, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 91. TE, treatment-experienced TN, treatment-naïve Efficacy of LDV-SOF in Patients With and Without NS5A RAVs at Baseline With cirrhosis With RAVs Treatment Naïve No RAVs Treatment Experience With RAVs No RAVs /7 5/8 1/1 7/7 8/9 19/19 LDV/SOF LDV/SOFRBV LDV/SOF LDV/SOFRBV LDV/SOF 1 weeks 4 weeks 1 weeks 4 weeks The largest impact of RAVs on treatment outcome was observed in patients with cirrhosis treated for 4 weeks of LDV/SOF (and no ribavirin) Zeuzem S, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract Vindico Medical Education
6 Integrated Analysis of the Prevalence and Impact of Baseline NS5A RAVs in Patients Treated with EBR-GZR GT1a: Population Sequencing Prevalence of NS5A RAVs = % EBR RAVs=~5% TN/relapsers EBR RAVs=~1% if TE non-responders GT1b: minimal impact of baseline EBR RAVs 1 8 ERB RAVs 1% No RAVs: 1/8 (9%) 97% 9% NS5A Class RAVs 1% No RAVs: 54/8 (79%) 9% 4% 1 8 ERB RAVs NS5A Class RAVs % 15% No RAVs: No RAVs: 51/5 44/5 (98%) (85%) 1% 1% 1% 1% EBR RAVs NS5A Class RAVs EBR RAVs NS5A Class RAVs Jacobson IM, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. 1 weeks EBR/GZR 1/18 weeks EBR/GZR RBV Toward a Cure for All Patient Populations Mark Sulkowski, MD Professor of Medicine, Medical Director of the Viral Hepatitis Center Johns Hopkins School of Medicine Baltimore, MD Retreatment with SOF and SMV of Patients Who Previously Failed on an HCV NS5A Inhibitor containing Regimen Week Week 1 Week 4 DCV failures SMV/SOF SVR1 N=1 Baseline characteristics N=1 Mean age, y (range) 54 (4 7) Male, n (%) 1 (81) G1a, n (%) 11 (9) G1b, n (%) () G4, n (%) (1) Median HCV RNA, 1 IU/mL 1.8 HCV RNA >8,, IU/mL, n (%) 14 (88) Severe fibrosis (FS kpa), n (%) 7 (44) Cirrhosis (FS>1.5 kpa), n (%) 9 (5) Median time between DCV-based (1 5) regimen and SMV/SOF, m (range) Presence of NS5A RAVs 1 (81) SVR1 According to Fibrosis Stage /15* 7/7 /8* Total No cirrhosis Cirrhosis SVR1 According to Genotype Presence of NS RAVs 8 (57)* 4 Prior HCV treatment, n (%) 1 (81) DCV/PR (19) DCV/ASV/PR 1/15* 8/1* / / *Available in 14 patients Total G1a G1b G4 *1 patient did not reach Week 1 FU Hezode C, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract Vindico Medical Education
7 Retreatment With SOF and SMV of Patients Who Previously Failed on an HCV NS5A Inhibitor containing Regimen Efficacy according to on-treatment response Rapid response n=1 Early response n-1 Late response n=5 (%) (%) (1%) SVR1: 9/9* SVR1: 1/1 SVR1: / <1 IUmL not detected: n= or <1 IUmL detected: n=5 or HCV RNA<1 IUmL HCV RNA<1 IUmL >1 IUmL: n= detected or not detected or not EOT SVR4 4 8 EOT SVR4 4 8 EOT SVR4 1 patient does not reach week-1 follow-up visit Abbot RealTime HCV assay was used Hezode C, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 11. Treatment failure cases (n=) Patient 1 Patient Gender Female Male Age G 1a 1a Cirrhosis Yes Yes (FS.8 kpa) (FS 14.9 kpa) Albumin 4.5 Platelets 7,, Prior tx DCV/PR DCV/ASV/PR On-tx Slow Slow response BL HCV RNA,84,1,9,157 IU/mL BL NS RAVs R155K Q8K, V17I BL NS5A M8T L1M RAVs SMV SOF was highly effective in this NS5A inhibitor-exposed population Treatment extension beyond 1 weeks and/or the addition of RBV in most difficult to cure? QUARTZ-I: Retreatment of HCV G1 DAA Failures With OBV/PTV/r DSV SOF Phase, multicenter study Open-label treatment G1a No cirrhosis OBV/PTV/r DSV N=14 SOF RBV G1a Cirrhosis OBV/PTV/r DSV SOF RBV N= G1b N= OBV/PTV/r DSV SOF G1b G1a OBV/PTV/r G1a OBV/PTV/r OBV/PTV/r Characteristic DSV SOF RBV DSV SOF RBV DSV SOF RBV 1 weeks, n=14 4 weeks, n= 1 weeks, n= Male, n (%) 8 (57) (1) 1 (5) Age, median years 59 (41 5) (54 4) 1 (59 ) BMI, median. (17.8.4).8 (.8 5.9) 1.4 (.7.) HCV RNA median log 1. (. 7.).55 ( ).9 (.5.) IU/mL IL8B non-cc, n (%) 1 (71) (1) (1) Fibrosis stage, n (%) F 1 (4) 1 (5) F () F (15) 1 (17) 1 (5) F4 (15) 5 (9) TE prior to previous 4 (9) (5) DAA, n (%) DAA-experienced pts G1 were enrolled, including with G1a and with compensated cirrhosis Characteristic cont. Relapse, n (%) Breakthrough, (%) Prior DAA regimen OBV/PTV/r OBV/PTV/r DSV SMV SOF SMV SAM RBV SOF RBV SOF PR TPV PR RAVs NS-Q8K NS-D18E/V NS5A-M8I/V NS5A-QE/H/R NS5A-L1M NS5A-H58D NS5A-Y9C/F/H NS5B-S55G NS5B-M414I/T NS5B-Y448H G1a OBV/PTV/r DSV SOF RBV 1 weeks, n=14 11 (79) (1) (14) 8 (57) 1 (7) 1 (7) (14) 9 (4) (14) 8 (57) 7 (5) (14) 4 (9) (14) 1 (7) G1a OBV/PTV/r DSV SOF RBV 4 weeks, n= (1) (1) 5 (8) 1 (17) () 1 (17) () G1b OBV/PTV/r DSV SOF RBV 1 weeks, n= 1 (5) 1 (5) 1 (5) 1 (5) 1 (5) 1 (5) 1 (5) Poordad F, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. QUARTZ-I: Retreatment of HCV G1 DAA Failures With OBV/PTV/r DSV SOF Virologic Response During and After Treatment At baseline, 17/ patients had at least 1 RAV in 1 of the DAA targets, while the remaining 5 had Q8K in NS, but no other RAVs present 7 patients had RAVs (other than NS Q8K) in targets patients had RAVs in all targets Overall HCV G1a HCV G1a HCV G1b No cirrhosis Cirrhosis These findings suggest that a multi-targeted treatment regimen can achieve high response rates in prior DAA failures, including those who previously failed D therapy, as well as those with persistent NS5A RAVs Poordad F, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. 15 Vindico Medical Education
8 % of Patients with Positive Urine Drug Screen % SVR1 (95% Cl) % of Patients with Positive Urine Drug Screen C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy Phase, randomized, parallel-group, placebo-controlled, double-blind trial Treatment naïve, GT1, 4, ; mixed genotypes of 1, 4, and allowed On opiate agonist therapy (OAT) for at least months, and consistently kept at least 8% of scheduled therapy appointments while on OAT Goal of % with cirrhosis and may be co-infected with HIV Immediate Treatment Arm EBR/GZR, n=1 Unblinding Follow-up for 4 weeks Deferred Treatment Arm Placebo, n=1 Unblinding EBR/GZR Follow-up for 4 weeks Dore G, et al. Presented at: AASLD 15; November 1-17; San Francisco, D1 W4 W8 W1 W1 W W8 W W5 CA. Abstract 4. C-EDGE CO-STAR: SVR 1 in the Immediate Treatment Group Modified Full Analysis Set (mfas) All GT GT1a* GT1b GT4 GT 189/ /15 8/9 11/11 /5 Failures Relapse Discontinuation Reinfection counted as success 5 LTFU or discontinued unrelated to Virologic Failure excluded from mfas analysis *Includes one subject with mixed infection (GT1 and GT1b) who achieved SVR1 Dore G, et al. Presented at: AASLD 15; November 1-17; San Francisco, CA. Abstract Urine Drug Screen Results: Day 1 to Treatment Week 1 Immediate Treatment Arm; EBR/GZR Treatment Phase Any drug use of 8 classes* Any drug use of 7 classes (excl. cannabinoids) Cannabinoids Benzodiazepines Opiates Deferred Treatment Arm; Placebo Phase *8 drug classes: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine, propoxyphene 1 Cocaine 1 Day 1 TW1 TW TW4 Tw TW8 TW1TW1 Time Point Amphetamines Day 1 TW1 TW TW4 Tw TW8 TW1 TW1 Time Point Time point of Demographics Fibrosis Stage GT at baseline UDS at baseline* UDS at TW1* GT at Follow-up detectable HCV RNA 48 yo Asian male NC 1a BZP, OPA BZP FW8 a yo white female NC 1a AMP,OPA FW8 1a 55 yo white female C 1a BZP, OPA BZP, OPA FW8 a 45 yo Asian male NC a OPA FW8 1b 7 yo Asian female NC a AMP, BZP, OPA AMP, BZP, OPA FW8 a Dore G, et al. Presented at: AASLD 15; November 1-17; San Francisco, CA. Abstract 4. C-EDGE CO-STAR 15 Vindico Medical Education
9 Patients, % Change from baseline (g/dl) C-EDGE Co-Infected: Phase Study of Elbasvir/Grazoprevir in Patients with HIV/HCV SVR4: Modified Full Analysis Set 1% 97.% 97.1% 1% 9.% 75% 5% 5% % All Patients GT1a GT1b GT4 All GT GT1a GT1b GT4 15/19 4/4 /7 /8 (97.%) (97.1%) (1%) (9.%) Relapse Excluded Reinfection 1 1 LTFU or discontinued unrelated to VF Rockstroh JK, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 1. SLAM C Randomized Open Label Prospective Clinical Pilot Study Interim Data: SOF LDV vs SOF SMV Combination Therapy in the Management of Acute HCV 9 patients with acute HCV SOF/LDV for 4 weeks (n=14) SOF/SMV for 8 weeks (n=15) Group A n=14 Group B n=15 Baseline characteristics SOF LDV SOF SMV Duration of therapy, weeks 4 8 Age, range (median) 18 9 (7) 4 (1) M:F BMI, %. 4. Caucasians Hispanic African American 9 1 Asian G1a 7 7 G1b 7 8 Mean viral load, k 1, 1, IL8b CC 4 IL8b CT 4 IL8b TT 9 Pre-Q8K (all G1a) Pre-5A polymorphism Post-Q8K (no changes) (no changes) Post-5A RAVs 1 Basu P, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 174. Undetectable Group A n=14 SOF LDV 4 weeks therapy Group B n=15 SOF SMV 8 weeks therapy Day 7, n, % 1/14, 9.9% 1/15, 9.% 4 weeks, n, % 14/14, 1% (ETVR) 14/15, 9.% (1 dropped, started IV drug use) 8 weeks, n, % 14/14, 1% 14/15, 9.% (ETVR) 1 weeks, n, % 14/14, 1% SVR1 14/15, 9.% weeks, n, % (per protocol) 1 dropped, 1/1, 1% SVR1 transferred to prison) (1 was LTFU homeless) Retention 1/14, 9.9% 1/15, 9.% Short course all oral therapy may be effective in acute HCV RUBY-I: Safety of OMB/PTV/RTV DSV for Treating HCV G1 Infection in Patients With Severe Renal Impairment or End-stage Renal Disease D ± RBV N= Male, n (%) 17 (85) Black, n (%) 14 (7) Age, years; median (range) (49 9) Hispanic or Latino ethnicity, n (%) (15) Degree of fibrosis, n (%) F F1 1 (5) F () F 4 () HCV VL, log 1 (IU/mL);. (5.5 7.) median (range) G1a, n (%) 1 (5) Hemoglobin, g/dl; mean (SD) 1. (1.8) CKD stage, n (%) 4 (egfr 15 ml/min/1.7m ) 8 (4) 5 (egfr <15 ml/min/1.7m or dialysis) 1 () On dialysis, n (%) 1 (5) egfr, ml/min/1.7m ; 1.9 ( ) median (range) Creatinine, mg/dl; median (range). (. 1.8) Hb change with D ± RBV mg/day BL W1WWW4 W W8 W1/EOT PTW4 G1b (DAA only) G1a (DAA RBV)* *8 of 14 patients held RBV Pockros PJ. Presented at: EASL 15; April -; Vienna, Austria. Abstract LO1. Pockros PJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract Vindico Medical Education
10 % Patients SVR1 (%) RUBY-I: OMB/PTV/RTV DSV for Treating HCV G1 Infection in Patients With Severe Renal Impairment or End-stage Renal Disease ITT Virologic Response, N= RVR EOTR SVR4 SVR1 Pockros PJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 19. An Update on Recently-approved and Emerging DAA Regimens K. Rajender Reddy, MD Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, PA The ASTRAL Trials: ASTRAL-1, SOF/VEL SOF/VEL (4 mg/1 mg) 1 Weeks ASTRAL-1 ASTRAL- ASTRAL- ASTRAL-4 GT 1,, 4 GT GT GT 1 CPT-B Cirrhosis Sofosbuvir (SOF); Nucleotide polymerase inhibitor Velpatasvir (VEL; GS-581); NS5A inhibitor SOF/VEL FDC: Once daily, oral, FDC (4/1 mg) 1 8 ASTRAL-1: SVR1 by Genotype Feld JJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. Feld JJ, et al. N Engl J Med. 15 [epub ahead of print]. Sulkowski MS, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 5. Mangia A, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 49. Charlton MR, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB relapse 1 relapse 1 death lost to follow-up 1 withdrew consent Total 1a 1b 4 5 Error bars represent 95% confidence intervals. Genotype Feld JJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. Feld JJ, et al. N Engl J Med. 15 [epub ahead of print]. 15 Vindico Medical Education
11 SVR1 (%) HCV RNA < LLOQ TD/TND (%) SVR1 (%) HCV RNA < LLOQ TD/TND (%) ASTRAL-: Genotype Treatment-naïve and Treatment-experienced Genotype HCV-infected patients, with and without Cirrhosis P=.18* /14 14/1 SOF/VEL SOF RBV * P value for superiority of SOF/VEL compared with SOFRBV Error bars represent 95% confidence intervals. Sulkowski MS, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 5. ASTRAL-: SVR1 by Cirrhosis or Treatment History SOF/VEL 91 SOF RBV relapses relapses 7 relapses 1 non-response 4 other relapses other 4 relapses 1 relapses 4 relapses 15 relapses other 8 other other 1 other No Yes Naïve Experienced Error bars represent 95% confidence intervals. Cirrhosis Status Treatment History Mangia A, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 49. ALLY- Study: Daclatasvir Plus Sofosbuvir Plus Ribavirin for 1 or 1 Weeks in HCV Genotype -Infected Patients With Advanced Fibrosis or Cirrhosis Phase Study SVR1: All Treated Patients ITT ANALYSIS (Primary Endpoint) Overall 1 Weeks 1 Weeks VBT a Relapse b 4 Death c a VBT (virologic breakthrough}: confirmed HCV RNA 1 log 1 IU/mL above nadir, or LLOQ if previously < LLOQ TD or TND; b Relapse: confirmed HCV RNA LLOQ at any posttreatment visit following < LLOQ TND at end of treatment; c Dilated cardiomyopathy on Day 7, not related to treatment OBSERVED ANALYSIS Overall 1 Weeks 1 Weeks VBT a Relapse b 4 Leroy V, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-. 15 Vindico Medical Education
12 SVR1 (%) SVR 1, % Patients SVR1, % Patients ASTRAL-4: GT 1- Treatment-naïve or -experienced Patients with CPT B Cirrhosis Overall SVR /9 SOF/VEL 1 week 8/87 77/9 SOF/VEL RBV SOF/VEL 1 week 4 week P value <.1 for comparison of SVR1 rate to 1% for each treatment group Charlton MR, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-1. SURVEYOR-I: HCV GT1 Non-Cirrhotic Treatment-naïve or -experienced Patients With ABT-49 and ABT-5 for 8 Weeks SURVEYOR-I Part 1: ITT SVR1 Rates ABT-49: pangenotypic HCV NS/4A protease inhibitor ABT-5: pangenotypic HCV NS5A inhibitor PT Week 4 Day 1 Week 1 Treatment period Post-treatment (PT) period n=9 ABT-49 mg ABT-5 4 mg n=4 ABT-49 mg ABT-5 1 mg 1% (9/9) treatment-experienced patients achieved SVR1 98% (49/5) treatment-naïve patients achieved SVR1 ABT-49 ABT mg 4 mg 4 4 mg 1 mg Poordad F, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-14. SURVEYOR-II: ABT-49 and ABT-5 In Non-cirrhotic Treatment-naïve and Treatment-experienced Patients With HCV Genotype Day 1 Week 1 PT Week 4 Treatment period Post-treatment (PT) period n= ABT-49 mg ABT-5 1 mg n= a ABT-49 mg ABT-5 1 mg ITT SVR1 Rates by Treatment n=1 ABT-49 mg ABT-5 1 mg RBV b n= ABT-49 mg ABT-5 4 mg 4 N=11. a Includes one patient who was incorrectly assigned to treatment in the GT cohort. b Daily dose of 1 mg or 1 mg RBV dosed BID based on patient body weight being <75 kg or 75 kg. open-label, multicenter Phase trial ABT-49 ABT-5 mg 1 mg mg 1 mg mg 1 mg RBV mg 4 mg Kwo PY, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract Vindico Medical Education
13 SVR1 (%) Patients, % ± Compensated Cirrhotic Patients With HCV GT 1, 4 or Infection Treated With Grazoprevir/Elbasvir: An Integrated Analysis 1 SVR1 Treatment Naïve Treatment Experienced Full analysis set No RBV RBV No RBV RBV No RBV RBV 1 weeks 1 weeks 1 or 18 weeks LTFU/Early Discon. 1 * % 9.% 9.% 9.5% 9.9% 1.% SVR1 (mfas ) (15/17) (8/1) (48/5) (74/8) (4/49) (49/49) Breakthrough 1 1 Rebound Relapse *Death (coronary artery disease) Death (lymphoma) n=1;discontinued due to noncompliance, n=1 mfas (modified full analysis set) excludes patients who discontinued treatment for reasons unrelated to study medication. Death (motor vehicle accident) D/C Due to Lab: ALT with increased eosinophils (8.8%) Jacobson IM, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract 4. C-CREST 1 & : Efficacy and Safety of Grazoprevir and MK-8 with Either Elbasvir or MK-848 in Patients with Chronic HCV GT1, or Phase, Randomized, Open-label clinical trials AIMS Part A of C-CREST 1 (GT1 and GT) and C-CREST (GT): Evaluated safety and efficacy of 8 weeks in treatment-naïve, noncirrhotic patients, using combinations of direct-acting antiviral drugs: 1. Grazoprevir (GZR), an NS/4A protease inhibitor. MK-8, an NS5B polymerase inhibitor. Elbasvir (EBR) or MK-848, NS5A inhibitors To select the regimen to be used in Part B of C-CREST 1 and, which will expand treatment into harder-to-treat patient populations Gane EJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB Week Regimen of GZR/MK-848/MK-8 (45 mg) Achieve High SVR1 Rates in GT1, GT & GT Compared to Prior 1-Week Regimens 1 Weeks GZR/EBR=RBV 8 Weeks GZR/MK-848/MK-8 ( mg) 8 Weeks GZR/MK-848/MK-8 (45 mg) * GT1 GT GT *Zeuzem S, et al. Ann Intern Med. 15;1:1-1. Brown A, et al. Poster presented at: EASL 15; April -, 15; Vienna, Austria. Poster P771. Gane E, et al. Poster presented at: EASL 15; April -, 15; Vienna, Austria. Poster P77. Gane EJ, et al. Presented at: AASLD 15; November 1-17, 15; San Francisco, CA. Abstract LB-15. C-CREST 15 Vindico Medical Education
14 Conclusions Thank you for participating Please complete the post test and evaluation to receive your CME credits 15 Vindico Medical Education
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationNew combination EBR/GZR: The end of an era for the difficult to treat?
New combination EBR/GZR: The end of an era for the difficult to treat? Ioannis Goulis Associate Professor in Gastroenterology Aristotle University of Thessaloniki, Greece 9 th International Congress of
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationNorah Terrault, M.D. Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah Terrault, M.D. Grants/Research Support AbbVie, Gilead, BMS,
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationStudy Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationThe ASTRAL Program Abstracts LB-2, LB-12, 205, 209
The ASTRAL Program Abstracts LB-2, LB-12, 5, 9 The ASTRAL Program FDC 1. 2. 3. 4. 5. SOF Nucleotide polymerase inhibitor VEL NS5A inhibitor ASTRAL1 GT1, 2, 4 6 ASTRAL2 GT2 Jacobson IM, et al. N Engl J
More informationHow to improve the access to therapy in South and East: Romania. Mihai Voiculescu. Romania
How to improve the access to therapy in South and East: Romania Mihai Voiculescu Romania 2 mil. Habitants; 5.6% HCV prevalence 99.5% GT1b 15 Internal Gross Revenue - Romania 124,7 139,7 132,6 131,5 124,1
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationAbstract LB-17. ALT / AST, Hemoglobin, Platelets, Serum Creatinine, Viral Load. Prior Treatment Regimen Co-morbid
Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network Nezam Afdhal, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationIndividual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL
Individual Optmizaton of therapy Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novarts, Springbank,
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationTreatment of Hepatitis C and Renal Disease
Treatment of Hepatitis C and Renal Disease David E. Bernstein, MD, FACG Vice Chair of Medicine for Clinical Trials Chief, Division of Hepatology and Director, Sandra Atlas Bass Center for Liver Diseases
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHepa%%s C elimina%on needs involvement of all turn the page. Graham R Foster Professor of Hepatology Queen Mary University of London
Hepa%%s C elimina%on needs involvement of all turn the page Graham R Foster Professor of Hepatology Queen Mary University of London Conflicts of Interest Speaker and consultancy fees received from AbbVie,
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More information